2 cheap shares that could be takeover targets in 2025

These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns.

| More on:
Young black colleagues high-fiving each other at work

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cheap shares often make great takeover targets. That’s because undervalued companies, particularly those with strong underlying assets, established market positions, or untapped potential, can offer significant opportunities for buyers.

These companies also present opportunities for retail investors, as shareholders can benefit from the rapid appreciation of share prices when takeover offers are made. Just look at Hargreaves Lansdown stock, which jumped 51% last year after the board agreed to a takeover in August.

So, here are two companies that I think could be takeover targets in 2025.

This gene-editing leader looks cheap

CRISPR Therapeutics (NASDAQ:CRSP) could be an attractive takeover target due to its low valuation and strong balance sheet. It’s also a world leader in gene therapies, with an approved gene-editing treatment, Casgevy, which could generate up to $3.9bn in annual revenue. In addition to Casgevy — the world’s first approved gene therapy — the company has a strong pipeline of treatments in development, including those targeting cancers and diabetes.

The above certainly suggests that CRISPR Therapeutics is undervalued, with a market cap only around $3.3bn. This relatively low valuation makes it an appealing acquisition target for larger healthcare companies looking to enter the gene-editing market. Moreover, with $1.9bn in cash and $200m in debt, this stock’s enterprise value is just $1.6bn.

What’s more, some analysts suggest there is a ready-made buyer in CRISPR’s partner on Casgevy, Vertex Pharmaceuticals. Now Vertex is a massive company with a market cap of $106bn and more than $6bn in cash. With Vertex responsible for 60% of Casgevy costs and set to take 60% of earnings, it may be something of a no-brainer to consolidate control over the programme — and the pipeline — through a takeover.

CRISPR is a stock I own, and while I’m tempted to buy more, my holding already represents significant exposure to the gene editing sector.

Discounted stock, full-price fashion

Most investors will be familiar with Burberry’s (LSE:BRBY) challenges over the past 12 months. The stock slumped on falling sales and challenges in China, where the economy appears to be missing its target.

With the share price significantly down from its highs — albeit up from recent lows — the stock is still being touted as a takeover target. In fact, in November 2024, there were rumours that the Italian skiwear company Moncler was interested in acquiring the British luxury brand Burberry.

In addition to its brand strength and unique positioning in British luxury, a takeover sounds feasible given the consolidation that already exists within the industry. Fashion houses like LVMH and Kering have acquired a host of luxury brands over the years, delivering economies of scale and synergies between things like skincare brands and high-end Belmond hotels.

Having rode Burberry shares to the peak, sold, and then bought again at a much lower price only to see them fall further (I sold again), I’m staying away from this iconic brand. However, I’m sure some investors will see an opportunity.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in CRISPR Therapeutics. The Motley Fool UK has recommended Burberry Group Plc, CRISPR Therapeutics, and Vertex Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

My favourite FTSE dividend stock just jumped 17%! So why am I sad?

This investor has mixed feelings today as a quality dividend stock from the FTSE 250 surged higher in his portfolio.…

Read more »

Investing Articles

Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were cheering.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Interest rates fall again! Here are 3 FTSE dividend growth shares to consider buying

As interest on cash savings becomes increasingly less attractive, Paul Summers has been looking at dividend growth shares for passive…

Read more »

Investing Articles

Up 10% today, I think this FTSE 250 growth share could continue to surge!

Babcock International's flying after upgrading its full-year forecasts. I think the FTSE 250 defence share might just be getting started.

Read more »

Investing Articles

The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's biggest company…

Read more »

Investing Articles

Is this my chance to buy Alphabet shares?

A big step up in AI spending at Google has investors nervous, but has it created an opportunity to buy…

Read more »

Senior woman potting plant in garden at home
Investing Articles

£10k in savings? Here’s how an investor could aim for a monthly second income of £1,200

Mark David Hartley considers how investors could build towards an early retirement plan with a second income from a portfolio…

Read more »